FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Marinomed Biotech AG FCF Yield % Related Terms
Marinomed Biotech AG FCF Yield % Historical Data
* Premium members only.
The historical data trend for Marinomed Biotech AG's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:MARI vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Marinomed Biotech AG's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marinomed Biotech AG FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Marinomed Biotech AG's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinomed Biotech AG (WBO:MARI) has a FCF Yield % of -6.01 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Marinomed Biotech AG and its competitors. According to the industry distribution chart, Marinomed Biotech AG ranks #578 out of 1415 companies in the Biotechnology industry, placing it in the top 40.8%.
Is Marinomed Biotech AG's FCF Yield % too high?
Marinomed Biotech AG's current FCF Yield % is -6.01. Based on the distribution chart, Marinomed Biotech AG ranks #578 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Marinomed Biotech AG has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #578 out of 1415 companies for FCF Yield %. This puts Marinomed Biotech AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Marinomed Biotech AG and its competitors. Marinomed Biotech AG's current FCF Yield % is -6.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (WBO:MARI) is currently considered Possible Value Trap. The stock's GF Value™ is €18.48, compared to a current price of €9.15 — trading 50.5% below its estimated fair value. The current FCF Yield % is -6.01. Marinomed Biotech AG's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Marinomed Biotech AG (WBO:MARI), the current FCF Yield % is -6.01 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?
Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued.
The current stock price of €9.15 is trading 50.5% below its estimated GF Value™ of €18.48.
GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.
Key valuation signals for WBO:MARI:
FCF Yield %: -6.01
GF Value™: €18.48 vs. price of €9.15 (50.5% below fair value)
No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
42GF Score
Get the complete analysis for WBO:MARI
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:MARI has been successfully added to your 
